S75RS04 Gene Therapy
Science Technology ITV Schools circa 1986.

By: Lammas Science

Read more:
S75RS04 Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Advances in gene therapy and the deepening understanding of cancer will see the oft-fatal disease becoming treatable in two decades, said cancer researcher Inder M. Varma.

Cancer mutations are being exposed cancer is in retreat through a combination of surgery, radiation, chemotherapy, molecular and genetic therapy, cancer will become a chronic disease rather than a terminal one, said Dr. Verma, a professor in Laboratory of Genetics at the Salk Institute for Biological Studies, at the Infosys Science Foundation Lecture at the National Centre for Biological Sciences here on Wednesday.

His optimism was elaborated through an intriguing cat-and-mouse game that played out for over five years of research into the Glioblastomas multiforme (GBM), a lethal form of brain cancer that kills the patient within 14 months.

Understanding GBM was critical as relapse, even after surgery or treatment, was certainty, said Prof. Verma.

The researchers at the Salk Institute developed a novel genetic technique to switch on genes in around five cells of a mouse brain to make them into cancer cells. The cells grew to all parts of the brain, but more importantly, they started to exhibit stem cell characteristics, said Dr. Verma.

Unlike the normal cell, a stem cell can divide into specialised cells a phenomenon that explains the resurgent ability of the GBM cancer. Even if you surgically remove the tumour, one cell is enough to recreate the cancer again, he explained.

Using gene therapy, the team of scientists attempted to block this ability as well as use drugs to block blood supply to the cancer cell. While the tumour did become smaller, it became even more invasive. Though the treatment did not work, the cancer cell did reveal the genes responsible for its invasiveness.

We began to genetically cut out the cancers invasiveness, and for the first time, experiments showed GBM cancer could be controlled This is an exciting area that can be possibly used to treat other forms of cancer, said Dr. Verma.

Please Wait while comments are loading...

1. Comments will be moderated by The Hindu editorial team. 2. Comments that are abusive, personal, incendiary or irrelevant cannot be published. 3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and'). 4. We may remove hyperlinks within comments. 5. Please use a genuine email ID and provide your name, to avoid rejection.

See more here:
Cancer set to become treatable: expert

Recommendation and review posted by Bethany Smith

National CyTOF Meeting 2014: TJ Chen, PhD, Cytobank
TJ Chen, PhD, Cytobank Cytobank: Enabling Single Cell Analysis and Personalized Medicine.

By: Icahn School of Medicine

See the rest here:
National CyTOF Meeting 2014: TJ Chen, PhD, Cytobank - Video

Recommendation and review posted by sam

Anthony L. Komaroff M.D.

DEAR DOCTOR K: I have leukemia. Thankfully, a family member was a bone marrow match. Can you tell me what to expect during my bone marrow transplantprocedure?

DEAR READER: A bone marrow transplant can be a life-saving treatment. To understand how it works, you need to understand how blood cells are created. And what leukemiais.

Your blood contains red and white blood cells. There are several types of white blood cells, which are a key part of your immune system. All your blood cells are made by blood stem cells, which live primarily in the spongy center of

You have viewed 20 free articles or blogs allowed within a 30-day period. FREE registration is now required for uninterrupted access.

S-R Media, The Spokesman-Review and Spokesman.com are happy to assist you. Contact Customer Service by email or call 800-338-8801

DEAR DOCTOR K: I have leukemia. Thankfully, a family member was a bone marrow match. Can you tell me what to expect during my bone marrow transplantprocedure?

DEAR READER: A bone marrow transplant can be a life-saving treatment. To understand how it works, you need to understand how blood cells are created. And what leukemiais.

Your blood contains red and white blood cells. There are several types of white blood cells, which are a key part of your immune system. All your blood cells are made by blood stem cells, which live primarily in the spongy center of your bigbones.

In the years before you got leukemia, each of your blood cells was programmed to live for a while, and then to die only to be replaced by new, youngcells.

Visit link:
Ask Dr. K: Bone marrow can save a life - Tue, 03 Mar 2015 PST

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/27gqxk/rnai) has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

RNAi can be rationally designed to block the expression of any target gene, including genes for which traditional small molecule inhibitors cannot be found. Areas of therapeutic applications include virus infections, cancer, genetic disorders and neurological diseases. Research at academic centers that is relevant to RNAi-based therapeutics is mentioned.

Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2014 to 2024. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 233 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 35 are involved in microRNAs. The bibliography contains selected 600 publications that are cited in the report. The text is supplemented with 38 tables and 12 figures.

Key Topics Covered:

Executive Summary

1. Technologies for suppressing gene function

2. RNAi Technologies

Read more from the original source:
Research and Markets: Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024

Recommendation and review posted by Bethany Smith

DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/s3s3t8/personalized) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2020.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2014-2024.

Profiles of 311 companies involved in developing technologies for personalized medicines, along with 565 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 73 tables and 25 figures.

Key Topics Covered:

Part I: Scientific & Commercial Aspects

View original post here:
Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024

Recommendation and review posted by Bethany Smith

Patrick Sullivan: Why care about psychiatric genetics?
A Stockholm Psychiatry Lecture held at Karolinska Institutet Feb 3 2015 by Prof. Patrick F Sullivan, UNC and KI. More lectures at https://www.youtube.com/Psy...

By: PsychiatryLectures

Visit link:
Patrick Sullivan: Why care about psychiatric genetics? - Video

Recommendation and review posted by Bethany Smith

DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/gxqhg9/gene_therapy) has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering.

Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression.

Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.

Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2014, over 2050 clinical trials have been completed, are ongoing or have been approved worldwide.A breakdown of these trials is shown according to the geographical areas and applications.

Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including germline gene therapy.

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2014-2024. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets

The voluminous literature on gene therapy was reviewed and selected 750 references are appended in the bibliography.The references are constantly updated. The text is supplemented with 75 tables and 15 figures.

Profiles of 181 companies involved in developing gene therapy are presented along with 223 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade.

Key Topics Covered:

More:
Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies

Recommendation and review posted by Bethany Smith

DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/rcv4lq/gene_therapy) has announced the addition of the "Gene Therapy Market, 2015 - 2025" report to their offering.

The "Gene Therapy Market, 2015-2025" report provides an extensive study on the marketed and pipeline gene therapies. A lot of research has been carried out in this field for over a decade but there are only five approved therapies (four available in Asian markets; one approved in the EU). There are many promising therapies which are currently being developed worldwide; the approach is likely to result in several commercial success stories in the foreseen future. The report covers various aspects, such as key players, marketed gene therapy products, products in clinical / pre-clinical research, associated ethical issues, likely future developments and upcoming opportunities for a variety of stakeholders.

Several disorders that arise inside the body are a result of either a direct genetic aberration or a dysfunctional/non-functional protein. The attempt to use nucleic acids to correct or delete the genes causing a particular disease is known as gene therapy. Although gene therapy has not contributed significantly to the global pharmaceutical market yet, it is anticipated to grow at a fast pace over the next decade.

Gendicine, developed by SiBiono GeneTech, was the foremost gene therapy that entered market in 2004 in China. Since then four more therapies have received approval in China, Philippines, Russia and the EU. This number for approved / marketed therapies seems weak at present; however, the strong and highly populated pipeline holds tremendous potential. There are 12 gene therapies in late stage of clinical development for the treatment of cancer, ocular and cardiovascular disorders.

There are several concerns that remain to be answered; examples include insertional mutagenesis, treatment of multigene disorders, curbing the risk of immune reactions, eugenics, high cost of therapy and ethical concerns related to making alterations at the genetic level. Despite this, gene therapy does offer a ray of hope for patients who either have no treatment options or show no benefits with drugs that are currently available. Such a benefit far outweighs any disadvantages that may be associated with this upcoming therapeutic field.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

Read the original:
Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies

Recommendation and review posted by Bethany Smith

Chronic ankle pain

By: Wasserman Chronic Pain and Regenerative Medicine

Read the original:
Chronic ankle pain - Video

Recommendation and review posted by sam

Arthritis Suffers Have a New Hope for Pain Relief
Arthritis Joint Pain: (541) 716-6469 https://plus.google.com/+ColumbiaPainManagementPCHoodRiver/ Arthritis Joint Pain suffers have a new hope for a pain free life. Dr Rigert talks about...

By: Trey Rigert

View post:
Arthritis Suffers Have a New Hope for Pain Relief - Video

Recommendation and review posted by Bethany Smith

Brown University biologists have determined how the loss of a gene in male mice results in the premature exhaustion of their fertility. Their fundamental new insights into the complex process of sperm generation may have direct applications to a similar loss of fertility in men.

What the team discovered is that the loss of the gene that makes the protein TAF4b causes a deficit in the number of progenitor cells at an embryonic stage of a male mouse's reproductive development. Lacking those important precursor cells means that the mice struggle to develop a robust stem cell infrastructure to sustain sperm production for the long term. The affected mice are fertile at first, but quickly deplete the limited sperm supply that they can generate.

"What's fascinating about these mice is they can reproduce," said Richard Freiman, senior author of the new study in the journal Stem Cells. "Mice can usually reproduce until they are two years old, but these mice can only reproduce until they are four months old."

TAF4b is a protein that affects how genes are regulated and transcribed, and its absence has profound impacts on the reproductive system. In previous work, Freiman's research group has shown that female mice without TAF4b are totally infertile and that their ovaries age prematurely. But in experiments with males, led by lab members Lindsay Lovasco and Eric Gustafson, the effect proved more subtle.

Sperm generation follows from a complex chain of events that the research shows begins before a male mouse is even born. In their experiments, the team compared the development of mice with and without the TAF4b gene. In mice with TAF4b, progenitor cells for sperm in the male embryo arise and proliferate normally, laying the groundwork in the testes for a robust pool of spermatogonial stem cells to develop. Those stem cells are the ones that produce a renewable supply of sperm. Without TAF4b, there were fewer progenitor cells and consequently fewer stem cells. They still produce sperm at first, but they can't renew production for the long haul. Ultimately the testes, which develop normally, become unproductive and atrophy.

What's not yet clear from the research is why the process fades out rather than just continuing, albeit at a very low level of productivity. One possibility is the low supply of spermatogonial stem cells drives the body to invest all its meager resources in immediate sperm production, leaving none of the stem cells in a more flexible state that can perpetually renew the supply. Another possibility is that regardless of supply, TAF4b is simply needed to see the renewal process through, for instance by maintaining some stem cells in their regenerative state.

Four Turkish brothers

Not only do humans have a gene for TAF4b, but a coincidental study last year in the Journal of Medical Genetics provides evidence that it also matters for sperm count. That research reported that four Turkish brothers who carried a mutation in the TAF4b gene had low sperm counts. Their mutation was in the same region of their gene as the one Freiman's team generated in the mice.

"The human implications are very exciting," he said. "It is possible that those men, as teenagers, were able to make functional sperm."

Certainly more research is needed, Freiman said, but if TAF4b mutation plays out in men the way it plays out in mice, his hope is that detecting the mutation in teenage boys could allow doctors to freeze their sperm so that when they are older and want to have children, they could draw on that banked supply.

Go here to see the original:
Mutation may cause early loss of sperm supply

Recommendation and review posted by Bethany Smith

Trieste team's breakthrough could lead to new AIDS drugs

(ANSA) - Trieste, March 2 - A group of researchers at Trieste's International Centre for Genetic Engineering and Biotechnology (ICGEB) has found the "dens" where HIV cells hide until they become "invisible". The breakthrough, which could lead to the development of new AIDS drugs, was made possible after the team, led by Professor Mauro Giacca, photographed the structure of HIV lymphoid cell nuclei. The study was published on Tuesday on the website of highly respected journal Nature. The AIDS virus manages to insert its DNA into the cells that it infects to become part of their genetic makeup. But up to now why the virus decides to combine with only some of the 20,000 human genes and how it manages to hide from medicines inside these genes had been a mystery.

Read the original here:
Italy study finds HIV's 'hiding places' - update

Recommendation and review posted by Bethany Smith

24 minutes ago Yunzhou Wei . Credit: Andrew Davis Tucker

An immune system that helps bacteria combat viruses is yielding unlikely results such as the ability to edit genome sequences and potentially correct mutations that cause human disease.

University of Georgia researchers Michael and Rebecca Terns were among the first to begin to study the bacterial immune system. They now have identified a key link in how bacteria respond and adapt to foreign invaders.

The new study, authored by the Terns and postdoctoral research associate Yunzhou Wei in the Franklin College of Arts and Sciences department of biochemistry and molecular biology, was published recently in Genes & Development.

A bacterium gains immunity against a virus through a sophisticated process of acquiring a fragment of the viral DNA and incorporating the sequence into its own genome. This virus identification sequence is kept in a locus commonly known as a CRISPR, short for clustered regularly interspaced short palindromic repeats.

CRISPR-associated proteins then use the sequence to recognize and destroy viruses.

A CRISPR-associated protein known as Cas9 destroys invading viral DNA and has been co-opted as a tool for programmable genome editing. This new tool provides a way to make gene deletions, corrections of mutations and additions of new genes in any genome.

The UGA study highlights the discovery of a new role of the Cas9 protein in the initial acquisition of the invader sequence.

"The recognition that this enzyme functions both in capture and in killing provides us with a link between those two processes that we think is involved in ensuring that the process is specific for the virus and avoids potential damage to its own genome," said Rebecca Terns, a senior research scientist in biochemistry and molecular biology. "Our findings implicate Cas9 in the recognition of a secondary, invader-confirmation signal called a PAM."

In the study, the team describes the basic set of machinery that is required to obtain a specific fragment of viral sequence and insert the fragment in a specific location.

View post:
Link identified between virus recognition, destruction in bacterial immune system

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise CHAPEL HILL, NC You might resemble or act more like your mother, but a novel research study from UNC School of Medicine researchers reveals that mammals are genetically more like their dads. Specifically, the research shows that although we inherit equal amounts of genetic mutations from our parents the mutations that make us who we are and not some other person we actually use more of the DNA that we inherit from our dads.

The research, published in the journal Nature Genetics, has wide implications for the study of human disease, especially when using mammalian research models. For instance, in many mouse models created for the study of gene expression related to disease, researchers typically dont take into account whether specific genetic expression originates from mothers or fathers. But the UNC research shows that inheriting a mutation has different consequences in mammals, depending on whether the genetic variant is inherited from the mother or father.

This is an exceptional new research finding that opens the door to an entirely new area of exploration in human genetics, said Fernando Pardo-Manuel de Villena, PhD, professor of genetics and senior author of the paper. Weve known that there are 95 genes that are subject to this parent-of-origin effect. Theyre called imprinted genes, and they can play roles in diseases, depending on whether the genetic mutation came from the father or the mother. Now weve found that in addition to them, there are thousands of other genes that have a novel parent-of-origin effect.

These genetic mutations that are handed down from parents show up in many common but complex diseases that involve many genes, such as type-2 diabetes, heart disease, schizophrenia, obesity, and cancers. Studying them in genetically diverse mouse models that take parent-of-origin into account will give scientists more precise insights into the underlying causes of disease and the creation of therapeutics or other interventions.

The key to this research is the Collaborative Cross the most genetically diverse mouse population in the world, which is generated, housed, and distributed from UNC. Traditional lab mice are much more limited in their genetic diversity, and so they have limited use in studies that try to home in on important aspects of diseases in humans. The Collaborative Cross bred together various wild type mice to create wide diversity in the mouse genome. Pardo-Manuel de Villena said that this diversity is comparable to the variation found in the human genome. This helps scientists study diseases that involve various levels of genetic expression across many different genes.

Gene expression connects DNA to proteins, which then carry out various functions inside cells. This process is crucial for proper human health. Mutations that alter gene expression are called regulatory mutations.

This type of genetic variation is probably the most important contributor not to simple Mendelian diseases where theres just one gene mutation [such as cystic fibrosis] but to much more common and complex diseases, such as diabetes, heart disease, neurological conditions, and a host of others, Pardo-Manuel de Villena said. These diseases are driven by gene expression, not of one gene but of hundreds or thousands of genes.

The Collaborative Cross and the expertise we have at UNC allow us to look at different gene expression for every gene in the genome of every kind of tissue, said Pardo-Manuel de Villena, who directs the Collaborative Cross.

See the article here:
Genetically Speaking, Mammals Are More Like Their Fathers

Recommendation and review posted by Bethany Smith

Science Documentary: Genetics, Robotics, Quantum Computing, Artificial Intelligence
Science Documentary: Genetics, Robotics, Quantum Computing, Artificial Intelligence There are several technologies emerging that will change what it means to...

By: ScienceRound

The rest is here:
Science Documentary: Genetics, Robotics, Quantum Computing, Artificial Intelligence - Video

Recommendation and review posted by Bethany Smith

Stem cells for life, Life Science Center

By: Cell Therapy Catapult

Read the original:
Stem cells for life, Life Science Center - Video

Recommendation and review posted by Bethany Smith

Noted chemist and biotech entrepreneur Peter G. Schultz, He spoke Wednesday, Feb. 25, at a conference held by the life science trade group Biocom.

In a rare appearance before the public, Peter G. Schultz showcased the drug research and preclinical activities at Calibr, the nonprofit biomedical research organization he directs.

Among the projects now under way:

-- A novel twist on the CAR T cell cancer therapy, using "blank" T cells that can be flexibly programmed by drugs given in vivo

-- A two-in-one multiple sclerosis therapy aimed at both controlling the disease's abnormal immune response and repairing damaged nerves

-- Treating spinal muscular atrophy with a Calibr-discovered compound that increases gene expression of the needed protein

Schultz, a prominent faculty member of the Scripps Research Institute known for his role in founding San Diego area biotechs, discussed what he was up to Wednesday at a life science conference held by Biocom, the San Diego-based life science trade group.

Calibr, the California Institute for Biomedical Research, was founded in 2012 with up to $90 million from Merck. The drug giant gets an option to exclusively license small molecule or antibody therapeutics from Calibr; the institute gets a financial base as it expands. It's located in Torrey Pines Mesa next to Synthetic Genomics.

Calibr is located at 11119 N Torrey Pines Rd #100, La Jolla, 92037 / Google Maps

The institution seeks a new way for drug discovery at non-for-profit research institutions, Schultz said at the luncheon presentation.

See the rest here:
Audacious start for La Jolla's Calibr

Recommendation and review posted by Bethany Smith

In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patients own blood.

Stem cells are so effective because they can become any cell in the body based on their environment.

"Since we started treating patients three years ago, some of the results we have seen have been miraculous," Professor Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, told The Sunday Times.

"This is not a word I would use lightly, but we have seen profound neurological improvements."

During the treatment, the patient's stem cells are harvested and stored. Then doctors use aggressive drugs which are usually given to cancer patients to completely destroy the immune system.

The harvested stem cells are then infused back into the body where they start to grow new red and white blood cells within just two weeks.

Within a month the immune system is back up and running fully and that is when patients begin to notice that they are recovering.

Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter Isla, now two.

But she claims the new treatment has transformed her life.

It worked wonders, she said. I remember being in the hospital... after three weeks, I called my mum and said: 'I can stand'. We were all crying.

See the rest here:
'Miracle' stem cell therapy reverses multiple sclerosis

Recommendation and review posted by Bethany Smith

The role of animal genetics for food nutritional qualities
Paul Boettcher, Livestock production officer at FAO on the role of animal genetics for food nutritional qualities FAO: http://www.fao.org.

By: Food and Agriculture Organization of the United Nations

More here:
The role of animal genetics for food nutritional qualities - Video

Recommendation and review posted by Bethany Smith

Published: Sunday, 3/1/2015 - Updated: 50 seconds ago

BY MARLENEHARRIS-TAYLOR BLADE STAFF WRITER

Hockey legend Gordie Howes star power is raising awareness in the United States and Canada about advances in stem-cell therapies as he continues what is being called a miraculous recovery from a massive stroke.

Those closest to him, including his son, Toledo radiologist Dr. Murray Howe, are convinced the former Detroit Red Wings player would have died if he had not traveled to a medical clinic in Tijuana, Mexico, for an experimental stem-cell treatment not yet available in the United States.

After a debilitating stroke on Oct. 26, Mr. Howe, 86, had a few weeks of slight recovery, but then his health went downhill quickly, said Dr. Howe, director of sports medicine imaging for ProMedica Toledo Hospital. The family had started preparing for his funeral. But that all turned around after he had the adult stem-cell treatment on Dec. 8.

If you saw him now, you wouldnt know he had a stroke, Dr. Howe said.

Its been wonderful. Every day I would say hes a little bit better, and there are little hints of improvement. Certainly in the first month, every day his strength, coordination, and balance were better. He has been eating like a horse. He had lost 20 pounds, and now he has gained back 25 pounds, so he is pretty close to his playing weight now, Dr. Howe said.

Amazing results

In describing his fathers treatment and recovery in the last three months, Dr. Howe does not hesitate to use words such as unbelievable, astonishing, and amazing.

Eight hours after Mr. Howe received what is called a lumbar puncture, where stem cells were injected in the spinal fluid of his lower back by an anesthesiologist, he went from being bedridden and only mumbling short sentences to speaking clearly and walking with assistance, Dr. Howe said.

Continued here:
Howe's recovery shows stem-cell advances

Recommendation and review posted by simmons

Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson
Stacy describes her outcome from stem cell therapy by Dr Harry Adelson for treatment of torn labrum of her shoulder and hip. http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read this article:
Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson - Video

Recommendation and review posted by simmons

In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patients own blood.

Stem cells are so effective because they can become any cell in the body based on their environment.

"Since we started treating patients three years ago, some of the results we have seen have been miraculous," Professor Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, told The Sunday Times.

"This is not a word I would use lightly, but we have seen profound neurological improvements."

During the treatment, the patient's stem cells are harvested and stored. Then doctors use aggressive drugs which are usually given to cancer patients to completely destroy the immune system.

The harvested stem cells are then infused back into the body where they start to grow new red and white blood cells within just two weeks.

Within a month the immune system is back up and running fully and that is when patients begin to notice that they are recovering.

Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter Isla, now two.

But she claims the new treatment has transformed her life.

It worked wonders, she said. I remember being in the hospital... after three weeks, I called my mum and said: 'I can stand'. We were all crying.

Visit link:
'Miracle' stem cell therapy reverses multiple sclerosis

Recommendation and review posted by simmons

THE contemporary age brings a lot of new things that leave people in awe, amazement, and sometimes, in disbelief and disagreement. One thing that the more advanced technology gave birth to is the controversial Stem Cell Therapy (SCT).

According to mayoclinic.org, SCT is the replacement of damaged or diseased stem cells by injecting or infusing healthy stems into your body.

An article from philstar.com also says that SCT replaces or supports ones degenerating tissues and organs. The stem cells used in this technology are capable of developing into different kinds of cells, thus, are also called master cells.

According to bethematch.org, the diseases that are treatable by SCT are leukemia, bone marrow diseases, inherited immune system disorders, and diseases with poorly functioning red blood cells.

SCT is also used as an anti-aging treatment. Some of the prominent Filipinos have used this therapy to maintain their youthful glow and energy.

In the Philippines, clinics offering SCT have sprouted like mushrooms due to its perceived benefits to the patients. In fact, Makati Medical Center has its Cellular Therapeutics Center, equipped with facilities from Germany, USA, and Japan.

In an article from makatimed.net, it was said that the center has an extensive range of services that boast the remarkable efficacy of stem cells.

Dr. Florencio Q. Lucero who started the use of adult SCT in the Philippines in 2006, was quoted in an article from inquirer.net saying that in the Philippines, most of the customers rich businessmen and public officials who are mostly males.

One of them is Manila Mayor Joseph Estrada. He had his SCT at a clinic in Germany called Villa Medica on April 2012. Another article from inquirer.net said that Estrada had 14 shots of blood from the donor animal, the unborn sheep, on his buttocks.

In the same article, Estrada was quoted saying he could sleep better, his knees are working better, and that his skin has shown its glow.

Here is the original post:
Animal cells for a younger you

Recommendation and review posted by simmons

General Information About Small Cell Lung Cancer (SCLC)

SCLC accounts for approximately 15% of bronchogenic carcinomas.

At the time of diagnosis, approximately 30% of patients with SCLC will have tumors confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes. These patients are designated as having limited-stage disease (LD).[1] Patients with tumors that have spread beyond the supraclavicular areas are said to have extensive-stage disease (ED).

SCLC is more responsive to chemotherapy and radiation therapy than other cell types of lung cancer; however, a cure is difficult to achieve because SCLC has a greater tendency to be widely disseminated by the time of diagnosis.

The overall incidence and mortality rates of SCLC in the United States have decreased during the past few decades.[2]

Estimated new cases and deaths from lung cancer (SCLC and non-small cell lung cancer [NSCLC] combined) in the United States in 2015:[3]

Lung cancer may present with symptoms or be found incidentally on chest imaging. Symptoms and signs may result from the location of the primary local invasion or compression of adjacent thoracic structures, distant metastases, or paraneoplastic phenomena. The most common symptoms at presentation are worsening cough, shortness of breath, and dyspnea. Other presenting symptoms include the following:

Symptoms may result from local invasion or compression of adjacent thoracic structures, such as compression involving the esophagus causing dysphagia, compression involving the laryngeal nerves causing hoarseness, or compression involving the superior vena cava causing facial edema and distension of the superficial veins of the head and neck. Symptoms from distant metastases may also be present and include neurological defect or personality change from brain metastases or pain from bone metastases.

Infrequently, patients with SCLC may present with symptoms and signs of one of the following paraneoplastic syndromes:

Physical examination may identify enlarged supraclavicular lymphadenopathy, pleural effusion or lobar collapse, unresolved pneumonia, or signs of associated disease such as chronic obstructive pulmonary disease.

Go here to see the original:
Small Cell Lung Cancer Treatment (PDQ) - National Cancer ...

Recommendation and review posted by Bethany Smith